MX2020007404A - Metodos y terapia de combincion para tratar cancer. - Google Patents

Metodos y terapia de combincion para tratar cancer.

Info

Publication number
MX2020007404A
MX2020007404A MX2020007404A MX2020007404A MX2020007404A MX 2020007404 A MX2020007404 A MX 2020007404A MX 2020007404 A MX2020007404 A MX 2020007404A MX 2020007404 A MX2020007404 A MX 2020007404A MX 2020007404 A MX2020007404 A MX 2020007404A
Authority
MX
Mexico
Prior art keywords
methods
combination therapy
treat cancer
patient
need
Prior art date
Application number
MX2020007404A
Other languages
English (en)
Inventor
Patrice A Lee
Shannon L Winski
David Chantry
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2020007404A publication Critical patent/MX2020007404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invencion se refiere a un metodo de tratamiento de cancer mediante la administracion a un paciente en necesidad del mismo, durante un periodo de tiempo, de agentes terapeuticos que consisten esencialmente de un inhibidor de MEK que es binimetinib o una sal farmaceuticamente aceptable del mismo, y un antagonista de union a PD-1, a un paciente en necesidad del mismo.
MX2020007404A 2018-01-10 2018-01-10 Metodos y terapia de combincion para tratar cancer. MX2020007404A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/013211 WO2019139581A1 (en) 2018-01-10 2018-01-10 Methods and combination therapy to treat cancer

Publications (1)

Publication Number Publication Date
MX2020007404A true MX2020007404A (es) 2020-09-14

Family

ID=67218727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007404A MX2020007404A (es) 2018-01-10 2018-01-10 Metodos y terapia de combincion para tratar cancer.

Country Status (13)

Country Link
US (1) US20200368205A1 (es)
EP (1) EP3737373A4 (es)
JP (1) JP2021516215A (es)
KR (1) KR20200106921A (es)
CN (1) CN111712243A (es)
AU (1) AU2018401608A1 (es)
BR (1) BR112020013912A2 (es)
CA (1) CA3087844A1 (es)
IL (1) IL275913A (es)
MX (1) MX2020007404A (es)
RU (1) RU2020126340A (es)
SG (1) SG11202006254QA (es)
WO (1) WO2019139581A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292596A1 (en) * 2021-02-10 2023-12-20 Curon Biopharmaceutical (Shanghai) Co., Limited Method and combination for treating tumors
CN114875143B (zh) * 2022-03-25 2024-06-07 中南大学 环状RNA circBRD7在制备鼻咽癌诊断和/或治疗制剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201840336A (zh) * 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
US20160013654A1 (en) * 2014-07-09 2016-01-14 Qualcomm Incorporated Dynamic power supply selection based on system requirements
CN106573060A (zh) * 2014-07-15 2017-04-19 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
CA2963281A1 (en) * 2014-10-03 2016-04-07 Novartis Ag Combination therapies
MX2018007423A (es) * 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.

Also Published As

Publication number Publication date
WO2019139581A1 (en) 2019-07-18
EP3737373A1 (en) 2020-11-18
SG11202006254QA (en) 2020-07-29
RU2020126340A (ru) 2022-02-10
RU2020126340A3 (es) 2022-02-10
AU2018401608A1 (en) 2020-07-16
CA3087844A1 (en) 2019-07-18
BR112020013912A2 (pt) 2020-12-22
CN111712243A (zh) 2020-09-25
EP3737373A4 (en) 2021-09-08
KR20200106921A (ko) 2020-09-15
JP2021516215A (ja) 2021-07-01
US20200368205A1 (en) 2020-11-26
IL275913A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
NZ739503A (en) A novel approach for treatment of cancer using immunomodulation
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2019011886A (es) Kit para el tratamiento o alivio de dolor en el sitio de incision despues de un procedimiento quirurgico.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2022000845A (es) Compuestos inhibidores.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
WO2018102687A3 (en) Combination therapy for treating cancer
CY1123861T1 (el) Θεραπευτικη αντιμετωπιση εξαψεων και οστικης απωλειας, επαγομενων απο θεραπεια στερησης ανδρογονων, με χρηση cis-κλομιφαινης
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2020003361A (es) Combinacion de un inhibidor parp y un antagonista de union al eje pd-1.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2020007404A (es) Metodos y terapia de combincion para tratar cancer.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2019003751A (es) Proteina terapeutica.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy